+44-1518-081136A novel antitumor protein from Calloselasma rhodostoma venom in Vietnam
2nd World Congress on TOXICOLOGY AND APPLIED PHARMACOLOGY
November 04-05, 2019 | Prague, Czech Republic
Kiem X Trinh
Vietnam Institute on Toxicology, USA
Posters & Accepted Abstracts : J Clin Exp Tox
DOI: 10.35841/2630-4570-C2-009
Abstract:
Introduction: There are over thirty thousand of snakebite
victims annually in Vietnam (VN). Two venomous
snake families cause the big medical problem. In this,
Calloselasma rhodostoma (CR) is the most dangerous
snake of viperidae. Therefore, since 2001, the scientific
research collaboration between VN and University of
Southern California (USC) has been established and
approved by VN government. The aim of the 1st project
was determined the technological process for purification
of disintegrin from CR venom of VN (CRd.VN), looking for a
new candidate drug of cancer treatment.
Method: The process of collection, lyophilization of CR
venom from VN. Its protein concentration was determined
by BCA assay. High Performance Liquid Chromatography
(HPLC), SDS-PAGE, Mass spectrometry (MS) analysis and
sequencing by tryptic digestion were used for purification
of CRd.VN and determined its molecular weight (MW) and
structure. Standard cell biological methods were employed
to characterize CRd’s abilities (in vitro) to inhibit platelet
aggregation, adhesion, migration and invasion of tumor
cells. The anti-cancer activities of CRd.VN in the breast
cancer (BC) of mice model (in vivo) were tested.
Results: The peak No 7 of HPLC (CRd.VN) showed a single
(MW≈10 kDa) band on SDS-PAGE gel. CRd.VN’s MW was
7.33 kDa. Its molecular structure and the sequence were
a monomer, containing 68 amino acids with RGD motif
(position 49-51) and 6 disulfide bonds. The anticancer
activities of CRd.VN were very strong and safe.
Conclusion: We have shown that CRd.VN is a possible antitumor
agent with clinical potential. The next step for CRd.VN
recombinant production, preliminary pharmacokinetics,
and toxicological properties are opening before coming to
a preclinical trial course.
Biography:
E-mail:
kiemtrinhxuan211@yahoo.comPDF HTML